Erlotinib extends survival of patients with relapsed non-small-cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2004年 / 18卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1077 / 1077
页数：1
相关论文
共 50 条
  • [21] Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey
    Batigun, O.
    Yildirim, E.
    VALUE IN HEALTH, 2007, 10 (06) : A234 - A234
  • [22] Second-line erlotinib for non-small-cell lung cancer
    Lorusso, Vito
    Cinieri, Saverio
    LANCET ONCOLOGY, 2012, 13 (04): : E141 - E142
  • [23] Clinical and economic review of erlotinib in non-small-cell lung cancer
    Yeung, Kai
    Carlson, Josh J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (04) : 411 - 423
  • [24] Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib
    Suleiman, Ahmed Abbas
    Frechen, Sebastian
    Scheffler, Matthias
    Zander, Thomas
    Kahraman, Deniz
    Kobe, Carsten
    Wolf, JRgen
    Nogova, Lucia
    Fuhr, Uwe
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 84 - 92
  • [25] Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
    Rudin, C. M.
    Cervantes, A.
    Dowlati, A.
    Besse, B.
    Ma, B.
    Costa, D. B.
    Schmid, P.
    Heist, R.
    Villaflor, V. M.
    Spahn, J.
    Li, S.
    Cha, E.
    Riely, G. J.
    Gettinger, S.
    ESMO OPEN, 2023, 8 (02)
  • [26] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
    Francesco Grossi
    Erika Rijavec
    Maria Giovanna Dal Bello
    Carlotta Defferrari
    Annalisa Brianti
    Giulia Barletta
    Carlo Genova
    Carmelina Murolo
    Maurizio Cosso
    Gabriella Fontanini
    Laura Boldrini
    Mauro Truini
    Paolo Pronzato
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1407 - 1412
  • [27] Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in patients with non-small-cell lung cancer
    Kishi, Hiroto
    Endo, Chihiro
    Sasaki, Ji-ichiro
    Saeki, Sho
    Iwamoto, Norihiro
    Inaba, Megumi
    Isobe, Takeshi
    Kourogi, Hirotsugu
    Saito, Hideyuki
    Hamada, Akinobu
    ANNALS OF ONCOLOGY, 2015, 26 : 84 - 84
  • [28] Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer
    Perez Carrion, Ramon
    Cubillo Gracian, Antonio
    Salinas Hernandez, Pedro
    CLINICAL LUNG CANCER, 2007, 8 (07) : 425 - 428
  • [29] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
    Grossi, Francesco
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Defferrari, Carlotta
    Brianti, Annalisa
    Barletta, Giulia
    Genova, Carlo
    Murolo, Carmelina
    Cosso, Maurizio
    Fontanini, Gabriella
    Boldrini, Laura
    Truini, Mauro
    Pronzato, Paolo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
  • [30] Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer
    van Leeuwen, Roelof W. F.
    Peric, Robert
    Hussaarts, Koen G. A. M.
    Kienhuis, Emma
    IJzerman, Nikki S.
    de Bruijn, Peter
    van der Leest, Cor
    Codrington, Henk
    Kloover, Jeroen S.
    van der Holt, Bronno
    Aerts, Joachim G.
    van Gelder, Teun
    Mathijssen, Ron H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1309 - +
12345